Here is a detailed look at Regeneron Pharmaceuticals, Inc. (ticker: REGN): the analyst consensus, key upcoming clinical/regulatory events, insider activity, and my take on whether it’s a “buy” (with caveats). As always, this is not financial advice — you should conduct your own due diligence and consider your risk profile.
✅ Analyst Recommendations
- The consensus among analysts is “Buy” (or equivalent). For example, as of October 10 2025, one source reports 23 analysts covering REGN with a consensus rating of “Buy” and an average 12‑month price target of $794.61, which implies about +40.7% upside from current levels.
- Some recent examples:
- Canaccord Genuity maintained a “Buy” rating on Oct 14 2025 with a price target of ~$745, ~30% upside.
- Citigroup upgraded the stock to “Buy” in May 2025, raising the target from $600 → $700.
- Some analysts are more cautious: for example, UBS has a “Neutral/Hold” at ~$595 target.
- Bottom line: Most analysts expect meaningful upside if things go well.
🧬 Important Events / Clinical Trials / Approvals Pending
There are several key upcoming or ongoing events for Regeneron that could move the stock materially — both positively and negatively.
Key items:
- Pipeline risk / setbacks
- The drug Itepekimab (with partner Sanofi) for COPD in former smokers: one Phase III trial met its primary endpoint (27% reduction in exacerbations at week 52) but a second trial failed to meet the same endpoint. That means regulatory approval is now more uncertain.
- The drug Odronextamab (for relapsed/refractory follicular lymphoma and diffuse large B‐cell lymphoma) received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) due to lack of confirmatory trial progress.
- A note: The company also expects manufacturing/third‑party site issues to delay approvals of other assets (e.g., Eylea HD) due to fill/finish inspection concerns.
- Upcoming studies / regulatory filings
- In its Q2 2025 results, Regeneron noted that a Phase 3 study for REGN7508 (an antibody to Factor XI) was initiated for prevention of venous thromboembolism after knee replacement; additional Phase 3 studies are planned for late 2025/first half 2026.
- They also flagged that although the Itepekimab trial had mixed results, they continue to evaluate data and will determine “next steps” for its COPD program.
- The company has several marketed products: e.g., Dupixent (immunology), Eylea (ophthalmology) — but both face future competitive or patent/biosimilar threats. Analysts note the importance of newer products ramping to replace any declines.
- Strategic developments
- Acquisition of 23andMe, Inc.’s assets for furthering genetic research (which may be longer‑term value but not necessarily near‐term major catalyst)
- Share buybacks & capital returns: not as much publicized as pipeline news, but companies with strong buy‑backs often get some investor favor.
What to watch:
- Are any of the delayed/failed trials salvaged via additional data or new trials?
- What are the upcoming readout dates for key assets (REGN7508, Itepekimab, other pipeline agents)?
- How are the legacy products performing in face of biosimilar/competitive pressure (especially Eylea) and can the new ones ramp quickly to offset?
- Manufacturing/regulatory issues: any new CRLs, delays, or regulatory surprises.
🔍 Insider Buying / Selling
- According to filings, there have not been significant insider purchases in the last 90 days for Regeneron.
- There was an insider sale: On Sep 3 2024, Director Arthur Ryan sold ~100 shares at ~$1,178.69/share.
- Many of the transactions listed are grants or small holdings by directors rather than major purchases/sales indicating strong “skin in the game.”
- No major recent disclosed purchase by insiders that suggests they are aggressively bullish from inside. Lack of insider buying is a mild caution.
🤔 My Suggestion: Buy or Not?
My view: I lean towards “cautious buy” for Regeneron — it has meaningful upside potential, but also notable risk. Here’s how I break it down:
Why I’d be willing to buy:
- Valuation looks moderately attractive given the pipeline and analyst upside (20‑40%+ possible).
- The company has strong base franchises (Dupixent, Eylea) that generate cash, and a robust internal discovery platform, which is a plus in biotech.
- Many analysts believe the company is transitioning into growth mode rather than just maintaining legacy products.
Why I’d remain cautious / hold back on full commitment:
- The mixed trial results (Itepekimab) and regulatory delays (Odronextamab) underscore the biotech risk: high upside, but also high uncertainty.
- Legacy revenue headwinds (especially for Eylea as biosimilars/patent expirations approach) could weigh if newer products do not ramp quickly.
- Insider activity doesn’t provide strong bullish signal via buying; manufacturing/regulatory issues are a recurring overhang.
- The “buy” recommendation comes with assumption that several futures catalysts will go well. If they don’t, the downside may be material.
Suggested approach:
- If you believe in the biotech pipeline and are comfortable with execution risk, you could initiate a partial position.
- Monitor key upcoming catalysts and trial readouts – if they go positively, you could scale up; if negative, consider stopping out or reducing.
- Keep the investment horizon at 12‑24 months or more, since pipeline ramp and regulatory outcomes take time.
- Consider using stop‑loss or risk control mechanisms: for instance, if a major data readout fails or regulatory delay escalates, you may want to reduce exposure.
📌 Conclusion
In summary:
- Analyst consensus is positive with meaningful upside potential (average targets ~$700‑$800+ depending on source).
- There are several important upcoming/ongoing clinical and regulatory events; success with these could be a big catalyst, but failures or delays pose risks.
- Insider buying is not strong; some modest selling exists, which adds a caution flag.
- My recommendation: Regeneron looks like a buy for those willing to tolerate biotech risks, but not a “slam‑dunk” with no risk. Treat it as a growth‑oriented speculative play rather than a safe income stock.